Back to top
more

biote Corp. (BTMD)

(Delayed Data from NSDQ)

$4.13 USD

4.13
179,850

+0.24 (6.17%)

Updated Aug 4, 2025 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (155 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Tilray Brands, Inc. (TLRY) Q4 Earnings Beat Estimates

by Zacks Equity Research

Tilray Brands (TLRY) delivered earnings and revenue surprises of +166.67% and -6.46%, respectively, for the quarter ended May 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is biote Corp. (BTMD) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Biote Corp. (BTMD) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

biote Corp. (BTMD) delivered earnings and revenue surprises of 33.33% and 3.51%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cerus (CERS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cerus (CERS) delivered earnings and revenue surprises of 20% and 2.95%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

InMode (INMD) Lags Q1 Earnings Estimates

by Zacks Equity Research

InMode (INMD) delivered earnings and revenue surprises of -6.06% and 0.61%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Biote Corp. (BTMD) Q4 Earnings Beat Estimates

by Zacks Equity Research

biote Corp. (BTMD) delivered earnings and revenue surprises of 11.11% and 2.85%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Myomo (MYO) delivered earnings and revenue surprises of 50% and 24.54%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Verano Holdings Corp. (VRNOF) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Verano Holdings Corp. (VRNOF) delivered earnings and revenue surprises of 42.86% and 0.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Agilent Technologies (A) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Agilent (A) delivered earnings and revenue surprises of 3.15% and 0.86%, respectively, for the quarter ended January 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

GE HealthCare Technologies (GEHC) Surpasses Q4 Earnings Estimates

by Zacks Equity Research

GE HealthCare (GEHC) delivered earnings and revenue surprises of 15.08% and 0.25%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is biote Corp. (BTMD) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how biote Corp. (BTMD) and Doximity (DOCS) have performed compared to their sector so far this year.

Zacks Equity Research

Should Value Investors Buy biote Corp. (BTMD) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Does biote Corp. (BTMD) Have the Potential to Rally 43.89% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for biote Corp. (BTMD) points to a 43.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Are Investors Undervaluing biote Corp. (BTMD) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

biote Corp. (BTMD) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for biote Corp. (BTMD), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks Equity Research

Wall Street Analysts Predict a 76.99% Upside in biote Corp. (BTMD): Here's What You Should Know

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 77% in biote Corp. (BTMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Is Cassava Sciences (SAVA) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Cassava Sciences, Inc. (SAVA) and biote Corp. (BTMD) have performed compared to their sector so far this year.

Zacks Equity Research

Is biote Corp. (BTMD) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Biote Corp. (BTMD) Beats Q3 Earnings Estimates

by Zacks Equity Research

biote Corp. (BTMD) delivered earnings and revenue surprises of 266.67% and 0%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Wall Street Analysts See an 88.04% Upside in biote Corp. (BTMD): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at an 88% upside potential for biote Corp. (BTMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Is biote Corp. (BTMD) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Zacks.com featured highlights include Steelcase Carriage Services, biote and Acme United

by Zacks Equity Research

Steelcase Carriage Services, biote and Acme United have been highlighted in this Screen of The Week article.

Moumita C. Chattopadhyay headshot

Buy These 4 Stocks With Rising Cash Flows for Big Gains

by Moumita C. Chattopadhyay

Cash indicates a company's true financial health. It is the key to its existence, development and success. SCS, CSV, BTMD and ACU are worth buying given their rising cash flows.

Zacks Equity Research

Zacks.com featured highlights include Ardmore Shipping, TXO Partners, GeoPark and biote

by Zacks Equity Research

Ardmore Shipping, TXO Partners, GeoPark and biote are part of the Zacks Screen of the Week article.

Zacks Equity Research

biote Corp. (BTMD) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

biote Corp. (BTMD) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.